Titan Pharmaceuticals Inc (TTNP)

[onlyimho]

Cost effectiveness of buprenorphine asserted by 2 authors

http://tandfonline.com/doi/full/10.1080/13696998.2017.1341416?src=recsys

The authors however have previously published with funding by Braeburn Pharmaceuticals.

"Results: BSI was associated with lower total costs (-$4,386), more QALYs (+0.031), and favorable INMB at all willingness-to-pay (WTP) thresholds considered. Higher drug acquisition costs for BSI (+$6,492) were outpaced, primarily by reductions in emergency room/hospital utilization (-$8,040) and criminality (-$1,212). BSI was cost-effective in 89% of PSA model replicates, and had a significantly higher NMB at $50,000/QALY ($20,783 vs $15,007; p?<?.05).

Conclusions: BSI was preferred over SL-BPN from a health-economic perspective for treatment of OUD in clinically-stable adults."

This has been "our" thought for a long time ... but not the market's ... yet ?